SCHEMBL1383588

SCHEMBL1383588

C=C(C(N)=O)c1ccc(F)cc1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 1/20 0.52
▸ CES1 P23141 1/20 0.52
▸ CA1 P00915 2/20 0.48
▸ CA2 P00918 2/20 0.48
▸ BCL2L1 Q07817 1/20 0.45
▸ BAD Q92934 1/20 0.45
▸ MAOB P27338 3/20 0.44
▸ MAOA P21397 2/20 0.44
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ KCNN4 O15554 1/20 0.43
▸ PTPN1 P18031 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ LTA4H P09960 1/20 0.42
▸ PKM P14618 1/20 0.41
▸ PARP10 Q53GL7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1450228 0.88 PARP10 (0.39) CA1CA2ALDH1A1PKMPARP10
SCHEMBL30584613 0.85 CES2 (0.46) CES2CES1CA1CA2BCL2L1
SCHEMBL18689505 0.80 CES2 (0.52) CES2CES1CA1CA2BCL2L1
SCHEMBL1382348 0.79 MAPT (0.50) CES2CA1CA2NPC1RAB9A
SCHEMBL10704727 0.79 CES2 (0.54) CES2CES1CA1CA2BCL2L1
SCHEMBL11798461 0.79 PARP10 (0.47) CA1CA2MAOANPC1RAB9A
SCHEMBL1033882 0.79 TSHR (0.57) CES2CES1CA1CA2ALDH1A1
SCHEMBL15679301 0.79 CES2 (0.68) CES2CES1CA1CA2BCL2L1
SCHEMBL8999129 0.79 CES2 (0.54) CES2CES1CA1CA2BCL2L1
SCHEMBL7621025 0.78 CES2 (0.59) CES2CES1MAOBMAOARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4188929-A1 SUBSTITUTED PYRROLO-PYRIDINONE DERIVATIVES AND THERAPEUTIC USES THEREOF Bayer Aktiengesellschaft (DE) 2023-06-07 — — EP claimed
JP-4828407-B2 — — 2011-11-30 — — JP claimed
EP-1594869-A2 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF Targacept, Inc. (US) 2005-11-16 — — EP claimed
WO-2004076449-A2 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF TARGACEPT, INC. (US) 2004-09-10 — — WO claimed
CN-118955381-A Pyrazole compound as well as preparation method and application thereof 赣南师范大学 2024-11-15 — — CN disclosed
CN-116685583-A Pyrimidine compounds, compositions and pharmaceutical uses thereof 缆图药品公司 2023-09-01 — — CN disclosed
EP-1725240-A4 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LTD (GB) 2009-03-25 — — EP disclosed
EP-1725240-A1 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2006-11-29 — — EP disclosed
EP-1594869-A2 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF Targacept, Inc. (US) 2005-11-16 — — EP disclosed
WO-2005094834-A1 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2005-10-13 — — WO disclosed
WO-2004076449-A2 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF TARGACEPT, INC. (US) 2004-09-10 — — WO disclosed
EP-0344577-A2 Butenoic or propenoic acid derivatives Eisai Co., Ltd. (JP) 1989-12-06 — — EP disclosed
Send feedback